Actualités Appili Therapeutics Inc - APLI | Actions TSX Venture Exchange

Appili Therapeutics to Commence Trading on Main Board of the TSX Exchange

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug...

Appili Submits Protocol for a Phase 3 Study Evaluating Favipiravir for the Treatment of Patients with COVID-19 Infections to ...

Company is committed to evaluating use of the broad-spectrum antiviral in the early treatment setting of COVID-19 to shorten the time to clinical...

Appili Therapeutics to Participate in Upcoming Investor Conferences for H.C. Wainwright & Co. and Maxim Group LLC

Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug...

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2021

Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug...

Appili Therapeutics Receives Eligibility for DTC Trading in the U.S.

Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug...

FDA Clears Appili Therapeutics to Expand its Phase 2 Clinical Trial of Favipiravir for the Potential Prevention of COVID-19 a...

U.S. expansion of antiviral outbreak control trial in long-term care facilities Favipiravir already approved in India and Russia for emergency...

Appili Prepares Canadian Long-Term Care Facilities to Enroll Participants in a Clinical Trial Evaluating Favipiravir as an Ou...

Site screening is required in advance of potential outbreaks in Ontario long-term care centers Only trial in the world investigating use of...

Appili Therapeutics Announces FY 2020 Annual and Financial Results

Company well-capitalized, reporting record level of capital support with over $27M CAN in equity financings Pipeline portfolio strengthened with...

Appili Therapeutics Commences Trading on the OTCQX Marketplace

Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the “Company” or “Appili”) is pleased to announce today that its common shares began trading...

Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COV...

Appili program designed to address the most urgent aspects of the COVID-19 public health threat First clinical study to examine the use of...

Appili Therapeutics Submits CTA with Health Canada to Sponsor Prophylactic Phase 2 Clinical Trial Evaluating FUJIFILM Toyama ...

First clinical program in the world designed to assess the use of favipiravir for COVID-19 as prophylaxis for outbreak control; antiviral drug...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Appili Therapeutics Inc (APLI)

Outils de qualité professionnelle, pour des investisseurs individuels.

APLI Actualités

Appili Therapeutics to Commence Trading on Main Board of the TSX Exchange

Appili Submits Protocol for a Phase 3 Study Evaluating Favipiravir for the Treatment of Patients with COVID-19 Infections to ...

Appili Therapeutics to Participate in Upcoming Investor Conferences for H.C. Wainwright & Co. and Maxim Group LLC

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2021

Appili Therapeutics Receives Eligibility for DTC Trading in the U.S.

FDA Clears Appili Therapeutics to Expand its Phase 2 Clinical Trial of Favipiravir for the Potential Prevention of COVID-19 a...

Appili Prepares Canadian Long-Term Care Facilities to Enroll Participants in a Clinical Trial Evaluating Favipiravir as an Ou...

Appili Therapeutics Announces FY 2020 Annual and Financial Results

Appili Therapeutics Commences Trading on the OTCQX Marketplace

Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COV...

Appili Therapeutics Submits CTA with Health Canada to Sponsor Prophylactic Phase 2 Clinical Trial Evaluating FUJIFILM Toyama ...

Appili Therapeutics to Present at Maxim Group’s Infectious Disease Virtual Conference

Appili Therapeutics Names Infectious Disease Specialist Yoav Golan, MD, as its Chief Medical Officer

Appili Therapeutics Reports Financial and Operational Results for Third Quarter Fiscal Year 2020

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Appili Therapeutics Inc (APLI) Actualités

Appili Therapeutics Inc (APLI)

Outils de qualité professionnelle, pour des investisseurs individuels.

APLI Actualités

Appili Therapeutics to Commence Trading on Main Board of the TSX Exchange

Appili Submits Protocol for a Phase 3 Study Evaluating Favipiravir for the Treatment of Patients with COVID-19 Infections to ...

Appili Therapeutics to Participate in Upcoming Investor Conferences for H.C. Wainwright & Co. and Maxim Group LLC

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2021

Appili Therapeutics Receives Eligibility for DTC Trading in the U.S.

FDA Clears Appili Therapeutics to Expand its Phase 2 Clinical Trial of Favipiravir for the Potential Prevention of COVID-19 a...

Appili Prepares Canadian Long-Term Care Facilities to Enroll Participants in a Clinical Trial Evaluating Favipiravir as an Ou...

Appili Therapeutics Announces FY 2020 Annual and Financial Results

Appili Therapeutics Commences Trading on the OTCQX Marketplace

Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COV...

Appili Therapeutics Submits CTA with Health Canada to Sponsor Prophylactic Phase 2 Clinical Trial Evaluating FUJIFILM Toyama ...

Appili Therapeutics to Present at Maxim Group’s Infectious Disease Virtual Conference

Appili Therapeutics Names Infectious Disease Specialist Yoav Golan, MD, as its Chief Medical Officer

Appili Therapeutics Reports Financial and Operational Results for Third Quarter Fiscal Year 2020

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application